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Abstract Recently it has been reported that macrophages
express a nuclear receptor, peroxisome proliferator-activated
receptor Q (PPARQ). Using a ligand of PPARQ, troglitazone or
pioglitazone, we have shown that the expression of two genes
involved in cholesterol biosynthesis, 3-hydroxy-3-methylglutaryl
coenzyme A (HMG-CoA) synthase and HMG-CoA reductase,
were increased by activation of PPARQ through a PPAR
response element (PPRE) in THP-1 macrophages. In addition,
treatment with troglitazone significantly increased the activity of
HMG-CoA reductase and the amount of intracellular cholester-
ol. Thus, we conclude that PPARQ and its agonists increase the
cholesterol content of macrophages by the increased expression
of genes involved in cholesterol biosynthesis. These findings
suggest that PPARQmay play a role in cholesterol metabolism in
macrophages. * 2002 Published by Elsevier Science B.V. on
behalf of the Federation of European Biochemical Societies.
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1. Introduction
Macrophages synthesize various proteins involved in lipid
metabolism, such as lipoprotein lipase (LPL) [1] and apolipo-
protein E [2]. These ¢ndings are observed not only in primary
cultured macrophages, but also in macrophages derived from
cloned cell-lines such as THP-1 cells [3,4]. However, the mech-
anism underlying their expression and the physiological role
of the gene products have not been fully understood.
Peroxisome proliferator-activated receptors (PPARs) are
transcription factors that function as important regulators
of cell di¡erentiation and energy homeostasis and act via a
PPAR responsive element (PPRE) in the promoter region of
target genes. There are several subtypes of PPAR and the
subtypes are expressed in a tissue-speci¢c manner. PPARQ is
known to be expressed primarily in adipose cells and to be an
adipogenic factor that regulates the expression of genes asso-
ciated with lipid metabolism, such as fatty acid binding pro-
tein and LPL [5,6].
It was reported that primary macrophages and THP-1-de-
rived macrophages express PPARQ [7]. Though the role of
PPARQ in macrophages remains unclear, e¡ects of PPARQ
on the regulation of gene expression in macrophages were
reported [8]. Speci¢cally, it was shown that the activation of
PPARQ by natural and synthetic agonists induced the expres-
sion of genes involved in lipid metabolism [9,10], such as the
macrophage-speci¢c receptor CD36, which has been proposed
to function as a scavenger receptor for modi¢ed low density
lipoprotein (LDL). Furthermore, PPARQ was recently re-
ported to be involved in cholesterol e¥ux in macrophages
[11]. These ¢ndings suggest a role for PPARQ as a modulator
of lipid metabolism in macrophages.
In the current study, using troglitazone or pioglitazone, a
synthetic agonist of PPARQ [12], we investigated the expres-
sion of two genes involved in cholesterol biosynthesis, 3-hy-
droxy-3-methylglutaryl-CoA (HMG-CoA) synthase and
HMG-CoA reductase, to assess the e¡ect of PPARQ on cho-
lesterol biosynthesis in THP-1 monocytic cells. We further
examined the e¡ect of troglitazone on the enzyme activity
and the cholesterol content in THP-1 macrophages.
2. Materials and methods
2.1. Materials
RPMI 1640, fetal calf serum (FCS), and phorbol-12-myristate-13-
acetate (PMA) were purchased from Sigma (St. Louis, MO, USA).
Troglitazone and pravastatin were obtained from Sankyo Pharma-
ceuticals (Tokyo, Japan), and pioglitazone was from Takeda Pharma-
ceuticals (Tokyo, Japan). The transfection reagent FuGENE1 6 was
obtained from Roche Diagnostics (Basel, Switzerland).
2.2. Cell culture
The human THP-1 monocytic leukemia cell-line was grown in
RPMI 1640 containing 10% FCS. Di¡erentiation of THP-1 cells
was induced by resuspending the cells in medium containing PMA
(40 ng/ml), which has been shown to induce the conversion of
THP-1 cells into mature cells functionally resembling macrophages
[13].
2.3. RNA analysis
To generate probes for Northern blot hybridization, the human
cDNA probes for HMG-CoA synthase, LPL, and acyl-CoA:choles-
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terol acyltransferase (ACAT) were constructed by reverse transcrip-
tion-polymerase chain reaction performed on RNA that had been
extracted from di¡erentiated THP-1 cells. A HMG-CoA reductase
cDNA was kindly provided by Dr. Shimano (Tsukuba University,
Tsukuba, Japan). Total RNA was isolated from cells at the indicated
times after induction of di¡erentiation, and 10 Wg of total RNA was
used for Northern blot hybridization. The results were normalized to
those of the 28S rRNA or the elongation factor-1K mRNA in each
sample.
2.4. HMG-CoA reductase assay
2U106 cells were seeded into culture dishes and maintained in me-
dium containing PMA (40 ng/ml) with or without troglitazone (10 WM)
for 24 h, then the cells were scraped into 50 mM TBS, pH 7.4. After
centrifugation, each pellet was frozen, then thawed in 0.1 ml bu¡er
containing 50 mM potassium phosphate, pH 7.4, 5 mM dithiothreitol,
5 mM EDTA, 0.2 M KCl, 0.25% Brij 96. After incubation for 10 min
at 37‡C, the suspension was centrifuged, and the supernatant contain-
ing an equal volume of protein (100 Wg) was subjected to measure-
ment of HMG-CoA reductase activity as previously described by
Brown et al. [14].
2.5. Decoy experiments
The PPRE ‘decoy’ was selected on the basis of binding of PPARQ to
PPREs, as reported previously [15,16]. Decoy (5P-GCG TCG ACA
GGG GAC CAG GAC AAA GGT CAC GTT CGG GAG TCG
ACG C-3P) or reverse control (5P-GCG TCG ACA GGG GAC
CAC TGG ATA CAG GAC GTT CGG CAG TCG ACG C-3P)
oligonucleotides were annealed to their respective complementary se-
quences. THP-1 cells were transfected with either decoy or reversed
oligonucleotides in various concentrations using the transfection re-
agent FuGENE1 6 for 6 h, according to the manufacturer’s protocol.
After the 6 h incubation, the cells were resuspended in fresh medium
containing PMA in the presence or absence of troglitazone, and gene
expression was examined by Northern blot analysis.
2.6. Cellular lipid measurements
THP-1 cells were seeded into six-well culture plates and maintained
in medium containing PMA (40 ng/ml) for 2 days, or maintained for a
longer period (5 days) in medium containing PMA for the ¢rst 2 days
and then in medium lacking PMA with or without various agents.
Cells were washed twice with phosphate-bu¡ered saline, then incu-
bated in 1 ml of isopropanol:hexane (2:3) for 1 h. The organic layer
was collected in a glass tube and dried under nitrogen. Dried extracts
were redissolved in the same volume of isopropanol:Triton X (9:1).
Total cholesterol (TC) and free cholesterol (FC) masses were mea-
sured with a colorimetric enzymatic assay kit (WAKO, Tokyo, Ja-
pan). The mass of esteri¢ed cholesterol (EC) was determined by sub-
tracting FC from TC.
2.7. Statistical analysis
All experiments were repeated at least twice and similar results were
observed in each experiment. The results are expressed as meanSS.D.
Group means were compared using Student’s t-test. A P-value of
6 0.05 was considered to be statistically signi¢cant.
3. Results
3.1. HMG-CoA synthase and HMG-CoA reductase expression
in THP-1 cells treated with a PPARQ agonist
Addition of PMA to THP-1 cells for 3 h induced a rapid
increase in mRNA levels for HMG-CoA synthase and HMG-
CoA reductase; following that, mRNA levels returned to the
nearly basal levels observed in undi¡erentiated THP-1 cells.
These results were consistent with the study of Wilkin et al.
[17]. In addition, treatment of cells di¡erentiated with PMA
with troglitazone resulted in signi¢cant increases in mRNA
for HMG-CoA synthase and HMG-CoA reductase (Fig. 1).
At the peak time (3 h), the levels of both genes were increased
about 1.6-fold upon incubation with troglitazone (10 WM),
and the decline in mRNA levels for these genes was less in
the presence of troglitazone (Fig. 1b). On the other hand,
treatment of undi¡erentiated THP-1 cells with troglitazone
alone did not result in a signi¢cant increase in mRNA levels
for these genes. We also examined the mRNA level of PPARQ
itself. It increased rapidly along with di¡erentiation of THP-1
cells, however, no signi¢cant di¡erence was observed in the
level of mRNA in the presence or absence of troglitazone. We
further investigated the e¡ect of troglitazone on the expression
of two other genes, ACAT and LPL. No signi¢cant di¡erence
was observed in the levels of these mRNAs regardless of the
presence of troglitazone (Fig. 1a).
Fig. 1. Induction of di¡erentiation-linked mRNA expression by tro-
glitazone in THP-1 cells. a: THP-1 cells, cultured in media contain-
ing PMA (40 ng/ml) to induce di¡erentiation, were treated with
(lane; +) or without (lane; 3) troglitazone (10 WM). Undi¡erenti-
ated THP-1 cells were also treated with troglitazone for 5 days and
analyzed (lane; TRO 5 days). Abbreviation of each gene is de-
scribed in the text. b: Changes in expression of HMG-CoA synthase
and HMG-CoA reductase in the absence (open circle) or presence
(closed circle) of troglitazone for 3 or 24 h are expressed as relative
increases. *P6 0.05, as compared with time-matched control cells.
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As shown in Fig. 2, troglitazone increased the expression of
mRNA of HMG-CoA synthase and HMG-CoA reductase in
a dose-dependent manner. Treatment with pioglitazone, which
had been reported to act through a PPARQ [18], also resulted
in a signi¢cant increase in the mRNA levels.
We also examined the e¡ect of troglitazone on HMG-CoA
reductase activity. The results showed that treatment with
10 WM of troglitazone for 24 h along with di¡erentiation in-
creased the enzyme activity of HMG-CoA reductase in THP-1
cells (Table 1). These results con¢rmed that the increase in
enzyme activity observed in cells was comparable to the in-
crease observed in mRNA.
3.2. E¡ects of the PPRE ‘decoy’ on expression of HMG-CoA
synthase and HMG-CoA reductase
It is assumed that the ‘decoy’ oligonucleotides can compete
for binding of activated PPARQ with the promoter region of
the gene and thus block PPAR-dependent transcriptional re-
sponses [19]. As shown in Fig. 3a,b, the mRNAs for HMG-
CoA synthase and HMG-CoA reductase after treatment with
PMA for 3 h were signi¢cantly suppressed in cells that were
transfected with decoy oligonucleotides. The e¡ect of the de-
coy was dose-dependent and 30 WM decoy suppressed mRNA
expression of both the HMG-CoA synthase and HMG-CoA
reductase by approximately 60%, as compared to the absence
of decoy, whereas transfection of 30 WM of reverse control
oligonucleotides caused no signi¢cant e¡ect on their expres-
sion.
To provide further evidence that a PPAR-dependent path-
way was involved in the increased expression of HMG-CoA
synthase and HMG-CoA reductase expression by troglita-
zone, we examined mRNA expression in cells transfected
with the indicated oligonucleotides in the presence or absence
of troglitazone (10 WM). Treatment with troglitazone caused
signi¢cant increases in mRNA for both genes in cells trans-
Fig. 2. Induction of HMG-CoA synthase and HMG-CoA reductase
expression by troglitazone or pioglitazone in THP-1 cells. THP-1
cells were treated with the indicated concentrations of troglitazone
(3^30 WM) (Tro) or pioglitazone (3 WM) (Pio) for 3 h. RNA levels
of HMG-CoA synthase and HMG-CoA reductase were normalized
by comparison with levels of 28S rRNA and are expressed as rela-
tive increases in comparison with the value of control cells, treated
with neither troglitazone nor pioglitazone. *P6 0.05 versus un-
treated control.
Table 1
Increase of HMG-CoA reductase activity by troglitazone in THP-1-
derived macrophages
HMG-CoA activity
(nM/Wg protein/min)
Di¡erentiation (3) 0.076S0.022
Di¡erentiation (+) 0.092S0.023
Di¡erentiation (+)+troglitazone 0.121S0.020*
THP-1 cells, cultured in medium containing PMA to induce di¡er-
entiation, were treated with or without troglitazone (10 WM) for
24 h. The HMG-CoA reductase activity are presented as meansS
S.D. *P6 0.05 versus undi¡erentiated THP-1 cells (n=4).
Fig. 3. E¡ect of the PPRE decoy oligonucleotide on expression of
HMG-CoA synthase and HMG-CoA reductase during di¡erentia-
tion of THP-1 cells. a: Undi¡erentiated THP-1 cells were trans-
fected with various concentrations (7.5^30 WM) of the decoy (decoy)
or 30 WM of reverse control (c) oligonucleotide. 6 h after transfec-
tion, quantities of the mRNA for HMG-CoA synthase and HMG-
CoA reductase were determined at the indicated times of di¡erentia-
tion (3 or 24 h). Cells not transfected with any oligonucleotide (3)
were also examined at 3 h. b: RNA levels, normalized by compari-
son with levels of 28S rRNA, are expressed as relative increases
(n=3). *P6 0.05, **P6 0.01 versus the cells treated with control
oligonucleotide. c: THP-1 cells transfected with the PPRE decoy (30
WM) (open circle) or control (30 WM) (closed circle) oligos were dif-
ferentiated in the presence of troglitazone (10 WM) for 3 or 24 h.
The RNA levels are expressed as relative increases in comparison
with the value of undi¡erentiated THP-1 cells. *P6 0.05 versus
time-matched cells transfected with the PPRE decoy.
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fected with the reverse control oligonucleotides, while the de-
coy inhibited the increase in expression (Fig. 3c).
3.3. E¡ect of a PPARQ agonist on accumulation of cholesterol
in THP-1 cells
To determine whether the increase in mRNA for the en-
zymes lead to a corresponding increase in intracellular choles-
terol, we measured TC and FC in THP-1 cells. After incuba-
tion in the presence of PMA for 2 days, THP-1 cells loaded
with troglitazone contained approximately 1.3-fold more TC
than cells not treated with troglitazone. However, no signi¢-
cant di¡erence was seen in FC, suggesting that the increased
cholesterol in cells treated with troglitazone was due to an
increase in EC (Fig. 4a). With prolonged incubation (for the
¢rst 2 days in the presence of PMA, and for three additional
days in the absence of PMA), a much greater accumulation of
cholesterol was observed in cells treated with troglitazone,
despite deprivation of PMA; approximately a 1.8-fold in-
crease in TC and a six-fold increase in EC were observed as
compared with untreated cells. These e¡ects of troglitazone on
cholesterol mass were dose-dependent, and pravastatin, a spe-
ci¢c inhibitor of HMG-CoA reductase, inhibited the increases
in TC and EC caused by treatment with troglitazone (Fig. 4b).
4. Discussion
Recent studies have demonstrated that PPARQ is expressed
in primary macrophages in vitro and in vivo [7,20] and is up-
regulated during di¡erentiation of monocyte into macro-
phages [21]. In addition, both natural and synthetic PPARQ
ligands are reported to regulate the expression of not only
genes associated with in£ammation, such as iNOS and
TNF-K [7,22], but also genes associated with phagocytic ac-
tivity, such as CD36 [8,23] in macrophages. These observa-
tions suggest that PPARQ plays an essential role in modulat-
ing the speci¢c functions of macrophages.
In THP-1 cells, not only the expression of HMG-CoA syn-
thase and HMG-CoA reductase but also the expression of
other genes involved in lipid homeostasis such as LPL [3,24]
and apolipoprotein E [3] are induced during the di¡erentiation
of this monocyte cell-line to macrophage-like cells by phorbol
esters. Thus, it had been thought that the expression of these
genes was mainly regulated through a PKC-dependent mech-
anism [17,25].
Recently, Tontonoz et al. reported that PPARQ ligands up-
regulate expression of the macrophage-speci¢c scavenger re-
ceptor, CD36, and promote uptake of modi¢ed LDL via
CD36 in THP-1 cells [8], suggesting a novel role of PPARQ
in gene regulation, di¡erentiation and lipid metabolism in
macrophages. Their studies showed that treatment of THP-1
cells with troglitazone alone resulted in a small increase in
CD36 mRNA, and the e¡ect of a combination of troglitazone
and phorbol ester was much greater than that of troglitazone
alone. In the present study, we obtained similar results ; tro-
glitazone increased the e¡ect of PMA on the expression of
HMG-CoA synthase and HMG-CoA reductase. As the in-
creased expression of these genes by troglitazone was inhibited
by a PPRE decoy, we suggest that the transcriptional response
was dependent on the interaction of PPARQ with PPRE. We
suggest that the expression of HMG-CoA synthase and
HMG-CoA reductase during the di¡erentiation of THP-1
cells are regulated as follows: ¢rst, PPARQ is induced by
phorbol ester through a PKC-dependent pathway, and then
troglitazone interacts with PPARQ and regulates the transcrip-
tion of mRNA, directly or indirectly. Interestingly, in our
experiment, levels of the mRNA for LPL were not increased
by troglitazone treatment despite this gene having been re-
ported to have an element recognized by PPARQ in its pro-
moter [26]. The reason why LPL mRNA was una¡ected is
unclear, but it might be due to a tissue-speci¢c transcriptional
regulation of this gene by distinct types of PPAR [6]. In fact,
PPARK and its agonists were reported to increase LPL gene
expression in macrophages [27]. It might also be the result of
di¡erent PPARQ subtypes. THP-1-derived macrophages re-
portedly express only PPARQ1 and PPARQ3 [28], whereas
LPL promoter is activated by PPARQ2 in other types of cul-
ture cells [26]. It is possible that LPL mRNA is mainly regu-
lated by PPARQ2.
In these experiments, we also demonstrated that activation
of PPARQ resulted in an increase of intracellular cholesterol
even in the absence of modi¢ed LDL, and that pravastatin
inhibited these increases in cholesterol caused by treatment
with troglitazone. This suggests that the increased amount
Fig. 4. The role of troglitazone on accumulation of cholesterol in
THP-1-derived macrophages. THP-1 cells were incubated for the
¢rst 2 days in the presence of PMA (a), and for three additional
days in the absence of PMA (b) with various concentrations of tro-
glitazone (1^10 WM) or with troglitazone (10 WM) and pravastatin
(30 WM). The amount of each type of cholesterol (TC, striped bar;
FC, open bar; EC, solid bar) was normalized by the value of total
cell protein (n=4). *P6 0.05, **P6 0.01, ***P6 0.005 versus
untreated control. 36 0.02 versus cells treated with troglitazone
(10 WM) only.
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of cholesterol by troglitazone observed in the present study
was the result of increased de novo synthesis, rather than the
uptake of modi¢ed LDL, or than its esteri¢cation by the
action of ACAT, because ACAT expression was not in-
creased. What is the meaning of increased cholesterol in mac-
rophages? Recently it has been reported that cholesterol is
essential for entry of mycobacteria into macrophages [29].
In this report, the authors demonstrate that the entry of my-
cobacteria is inhibited in macrophage depleting its cholesterol.
Therefore, increase of the mRNAs for cholesterogenic genes
by activated PPARQ may play an important role in the acqui-
sition of some macrophage-speci¢c abilities, such as phagocy-
tosis. Moreover, it has been recently reported that the expres-
sion of PPARQ is observed in atherosclerotic legions co-
localized with macrophages [20,28], and that PPARQ ligand,
troglitazone, signi¢cantly inhibits the development of athero-
sclerotic foam cell lesions [30^32]. However, troglitazone ex-
erted apparently an opposite e¡ect in the current experiments.
The anti-atherogenic e¡ects of PPARQ ligand appear to be
mediated by favorable changes in the extracellular environ-
ment such as the suppression of hyperinsulinemic hyperglyce-
mia, in£ammation and oxidation [22,33]. To understand the
complex roles of PPARQ in the process of atherosclerosis,
further studies on cholesterol metabolism in macrophages
are needed.
In conclusion, we demonstrated for the ¢rst time that the
expression of two genes involved in cholesterol metabolism,
HMG-CoA synthase and HMG-CoA reductase, is increased
by a ligand of PPARQ, troglitazone, in macrophages. Our
results also showed that the activity of HMG-CoA reductase,
which is important in the regulation of intracellular cholester-
ol mass, and the cholesterol content were concomitantly in-
creased by troglitazone. An increase in intracellular cholester-
ol may contribute to regulation of macrophage-speci¢c
functions or regulation of atherogenesis.
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